

## **ASX Announcement**

### **Melbourne Investor Briefing Invitation**

---

**6 October 2022** – Race Oncology Limited (“Race”) is pleased to invite shareholders and interested investors to attend a special in-person investor briefing.

The briefing will be conducted by Race’s CEO, Mr Phil Lynch and CSO, Dr Daniel Tillett who will provide an overview on recent activities and the Company’s future plans. The formal presentation will be followed by an interactive Q+A plus a networking session with refreshments.

Shareholders and interested investors are invited to submit questions to be addressed during the event via Race’s [Investor Hub](#).

#### **Briefing details**

Date/time: Thursday, 20 October, from 6pm-8.30pm (AEST)

Location: Fresh Equities Offices, Level 16, 452 Flinders St, Melbourne

Registration link: <https://events.humanitix.com/race-oncology-shareholder-briefing>

Once the registration form is completed, investors will receive a confirmation email with further details about the event.

The Race team looks forward to meeting all those investors who can attend.

-ENDS-

#### **About Race Oncology (ASX: RAC)**

Race Oncology is an ASX listed precision oncology company with a Phase 2/3 cancer drug called Zantrene®.

Zantrene is a potent inhibitor of the Fatso/Fat mass and obesity associated (FTO) protein. Overexpression of FTO has been shown to be the genetic driver of a diverse range of cancers. Race is exploring the use of Zantrene as a new therapy for melanoma and clear cell renal cell carcinoma, which are both frequent FTO over-expressing cancers.

In breakthrough preclinical research, Race has also discovered that Zantrene protects from anthracycline-induced heart damage, while in tandem acting with anthracyclines and proteasome inhibitors to improve their ability to target cancer.

The Company also has compelling clinical data for Zantrene as a chemotherapeutic agent and is in two clinical trials in Acute Myeloid Leukaemia (AML).



Race is pursuing outsized commercial returns for shareholders via its 'Three Pillar' strategy.

Learn more at <https://www.raceoncology.com>

*Race encourages all investors to go paperless by registering their details with the Company's share registry, Automic Registry Services, at [www.automicgroup.com.au](http://www.automicgroup.com.au)*

**Release authorised by:**

Phil Lynch, CEO/MD on behalf  
of the Race Board of Directors  
[phillip.lynch@raceoncology.com](mailto:phillip.lynch@raceoncology.com)

**Media contact:**

Jane Lowe  
+61 411 117 774  
[jane.lowe@irdepartment.com.au](mailto:jane.lowe@irdepartment.com.au)